New Naurex spin-off grants Allergan first rights to NMDA modulators; Aptinyx launched
Allergan PLC received first rights to in-license N-methyl-D-aspartic acid (NMDA) modulators discovered by a yet-to-be named spin-off of Naurex Inc.
- Drug Discovery Tools
- Large Molecule
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.